anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Obesity in the United States and Western countries represents a major health challenge associated with an increased risk of metabolic diseases, including cardiovascular disease, hypertension, diabetes, and certain cancers. Our past work revealed a more pronounced obesity-cancer link in certain ethnic groups, motivating us to develop a tailored dietary intervention called the Healthy Diet and Lifestyle 2 (HDLS2). The study protocol is described herein for this randomized six-month trial examining the effects of intermittent energy restriction (5:2 Diet) plus the Mediterranean dietary pattern (IER + MED) on visceral adipose tissue (VAT), liver fat, and metabolic biomarkers, compared to a standard MED with daily energy restriction (DER + MED), in a diverse participant group. Using MRI and DXA scans for body composition analysis, as well as metabolic profiling, this research aims to contribute to nutritional guidelines and strategies for visceral obesity reduction. The potential benefits of IER + MED, particularly regarding VAT reduction and metabolic health improvement, could be pivotal in mitigating the obesity epidemic and its metabolic sequelae. The ongoing study will provide essential insights into the efficacy of these energy restriction approaches across varied racial/ethnic backgrounds, addressing an urgent need in nutrition and metabolic health research. Registered Trial, National Institutes of Health, ClinicalTrials.gov (NCT05132686).
Vortioxetine 2.5 mg, 5 mg or 10 mg, encapsulated tablets, orally, once daily for up to 52 weeks. For the first week of treatment all participants received 5 mg/day vortioxetine, thereafter, the dose could be increased to 10 mg/day or decreased to 2.5 mg/day, based on participant's response and tolerability as judged by the investigator.
In 30 patients; Inguinal hernia surgery will be performed with the eTEP method and the 15x12x10 cm polyprolene patch used in this surgery will be marked with small metallic clips from the lateral, superomedial and inferomedial sides. During the surgery, the mesh will not be fixed to the Cooper ligament. Patients whose pain scores (VAS score) are measured on the first postoperative day and who are suitable for discharge will be discharged after a pelvis x-ray is taken. One month after the surgery and 6 months later, patients will be called to the outpatient clinic and examined, their pain scores will be measured (VAS score) and pelvic radiographs will be taken. The movement of the clips marked on the patch will be compared with previous radiographs in cm.
PROBLEM TO BE SOLVED: To effectively treat the disturbed metabolism of biotissue occurring in the oxidation function insufficiency of cells by administrating the amt. of a medicine at which the oxidation function of the cells can be altered while measuring and monitoring the oxidation function of the cells. SOLUTION: The information indicating the oxidation function of the cells, more particularly the redox state of cytochromes a, a3 and the oxyhemoglobin concn. of mitochondrial membranes are measured by a spectrometer 22 using near infrared (NIR) spectrometry and a computer 24. Namely, the NIR light generated in the spectrometer 22 is transmitted through a catheter and is guided to the tissue to be monitored from a probe 10. Some of the NIR light is reflected to the distal end of a sheave connector and is returned to the spectrometer 22. The change in the absorption unit of the cytochromes a, a3 and the oxyhemoglobin with time is calculated by the computer 24. The medicine consisting of oxygen, thiosulfate ion, methylene blue, etc., is administered in accordance with the result of the calculation, by which the oxidation function of the cells is altered.
Healthy individuals \< 40 years of age. Vaccinated with 3 doses FSME immune Adult intramuscular injection according to the standard recommended primary vaccine at time 0, 1, and 7 months.
FIELD: chemistry of natural compounds. SUBSTANCE: hen egg yolks were homogenized in acetone at temperature from -20 to -25 C for 3 min. Process is repeated 6 times. Then egg yolk is extracted with ethanol at 24-28 C in inert gas atmosphere for 1.5 hr. Obtained after filtration the cleared solution is precipitated with cadmium chloride. Precipitate is reprecipitated 5 times with ethanol containing cadmium chloride, dissolved in chloroform and treated with 30% ethanol solution. Method is used for lecithin (phosphatidyl choline) preparing. EFFECT: increased yield of the end product, improved quality. 3 tbl
Patients receive olaparib orally (PO) twice daily (BID). Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
The placebo products are common wheat-maize cookies (2 g RS). Nine young healthy volunteers (males and females) consumed placebo in two separate occasions.
Patients receive docetaxel IV over 1 hour on day 1. Cycles repeat every 3 weeks in the absence of disease progression or unacceptable toxicity. Patients who experience disease progression may crossover to Arm I and receive bintrafusp alfa alone.
Early diagnosis and prompt management are essential to enhance the outcomes of patients with sepsis and septic shock. Over the past two decades, evidence-based guidelines have guided appropriate treatment and recommended the implementation of a bundle strategy to deliver fundamental treatments within the initial hours of care. Shortly after its introduction, the implementation of a bundle strategy has led to a substantial decrease in mortality rates across various health care settings. The primary advantage of these bundles is their universality, making them applicable to all patients with sepsis. However, this same quality also represents their primary disadvantage as it fails to account for the significant heterogeneity within the septic patient population. Recently, the individualization of treatments included in the bundle has been suggested as a potential strategy for further improving the prognosis of patients with sepsis. New strategies for the early identification of microorganisms and their resistance patterns, advanced knowledge of antibiotic kinetics in critically ill patients, more conservative fluid therapy in specific patient populations, and early use of alternative vasopressors to catecholamines, as well as tailored source control based on patient conditions and site of infection, are potential approaches to personalize initial care for specific subgroups of patients. These innovative methodologies have the potential to improve the management of septic shock. However, their implementation in clinical practice should be guided by solid evidence. Therefore, it is imperative that future research evaluate the safety, efficacy, and cost-effectiveness of these strategies.
Implantation of cardiac devices is usually considered to be a safe procedure. Rare complications, such as pneumothorax, may occur after the procedure. The association with pneumopericardium or pneumomediastinum is even more uncommon. We present the case of a patient in his 70s, on haemodialysis, admitted for complete atrioventricular block. He underwent implantation of a dual-chamber pacemaker. He presented with chest pain the day after implantation. Chest CT scan revealed a pneumothorax associated with a pneumopericardium and pneumomediastinum 'pan pneumo', due to an atrial perforation. We opted for a conservative management strategy. Repeat CT scan of the chest 8 days after the procedure showed a complete resorption of the 'pan pneumo'. The objective of this case report is to describe this rare complication and provide further insight into its management, particularly in the absence of specific guidelines.
Extracellular vesicles (EVs) are small phospholipid bilayer-bond structures released by diverse cell types into the extracellular environment, maintaining homeostasis of the cell by balancing cellular stress. This article provides a comprehensive overview of extracellular vesicles, their heterogeneity, and diversified roles in cellular processes, emphasizing their importance in the elimination of unwanted molecules. They play a role in regulating oxidative stress, particularly by discarding oxidized toxic molecules. Furthermore, endoplasmic reticulum stress induces the release of EVs, contributing to distinct results, including autophagy or ER stress transmission to following cells. ER stress-induced autophagy is a part of unfolded protein response (UPR) and protects cells from ER stress-related apoptosis. Mitochondrial-derived vesicles (MDVs) also play a role in maintaining homeostasis, as they carry damaged mitochondrial components, thereby preventing inflammation. Moreover, EVs partake in regulating aging-related processes, and therefore they can potentially play a crucial role in anti-aging therapies, including the treatment of age-related diseases such as Alzheimer's disease or cardiovascular conditions. Overall, the purpose of this article is to provide a better understanding of EVs as significant mediators in both physiological and pathological processes, and to shed light on their potential for therapeutic interventions targeting EV-mediated pathways in various pathological conditions, with an emphasis on age-related diseases.
The present invention provides an isolated nucleic acid sequence encoding saitohin (STH), an isolated nucleic acid sequence that hybridizes to said sequence, and a purified protein encoded by said nucleic acid sequences. The present invention also provides a purified STH protein, and a method of making STH protein. The present invention is further directed to an antibody specific for STH, and a method for producing said antibody. Additionally, the present invention discloses a vector comprising a nucleic acid sequence encoding STH, a host cell transformed with said vector, and transgenic nonhuman animals. The present invention further provides methods for determining whether a subject has, or is at increased risk for developing, a neurodegenerative disease, and for assessing said subject's prognosis. Finally, the present invention discloses kits for determining whether a subject has, or is at increased risk for developing, a neurodegenerative disease.
FIELD: medicine, pharmacy. SUBSTANCE: invention relates to preparing dimer of molecular variant of apo-lipoprotein AI-Milano that can be used for making drugs used for prophylaxis and treatment of patients with atherosclerosis and cardiovascular diseases. The claimed dimer exhibits purity, at least 90%, but preferably at least 98%. Dimer of apo-lipoprotein AI-Milano is prepared from donor blood or by recombinant technology in an expression system in E. coli or as an intracellular fused protein in E. coli. Pharmaceutical composition containing dimer of apo-lipoprotein as an active component can has additionally a carrier and/or stabilizing agent, preferably of lipid nature, and/or an agent decreasing lipid content in the body. Dimer-containing pharmaceutical composition can be used for treatment of patients with atherosclerosis and cardiovascular diseases as prodrug for apo-lipoprotein monomer for thrombosis prophylaxis. Method ensures to obtain dimer of apo-lipoprotein as a pure form showing the prolonged half-time period in plasma and improved capability to promote fibrin splitting in the body as compared with that of monomer. EFFECT: improved properties and effectiveness of dimer. 27 cl, 13 dwg, 9 tbl, 10 ex
OBJECTIVES: The prostatic urethral lift (PUL) has been used as a minimally invasive surgery for benign prostatic hyperplasia (BPH) since April 2022 in Japan. This study evaluated the initial outcomes and surgical techniques of PUL for BPH.
METHODS: In this prospective, single-center study, indications were based on the proper use guidelines for PUL in Japan. Preoperative patient status, postoperative progress at 1 and 3 months, and perioperative complications were evaluated. The surgical technique was changed twice, and the subgroup analysis and technique were evaluated.
RESULTS: Of the 50 patients who underwent surgeries performed by a single surgeon, the median age and prostate volume were 71 years and 42.0 mL, respectively. Furthermore, the median operative time and number of implants used were 20 min and 5, respectively. No postoperative fever or severe hematuria requiring reoperation occurred. All patients were discharged from the hospital the day following the PUL, as scheduled. Postoperative International Prostate Symptom Score, quality of life score, maximum flow rate, and postvoid residual volume at 1 and 3 months were significantly improved compared with the preoperative values. A significant improvement in maximum flow rate was observed in the subgroup analysis from 1 month postoperatively in the group with an anterior channel creation focus.
CONCLUSIONS: PUL is effective and safe in cases with prostate volumes of <100 mL. Lifting the bladder neck is important for opening an anterior prostatic urethral channel and improving urinary function during the early postoperative period.
Patients registered to the study will receive an assigned dose of everolimus by mouth and RCHOP for a maximum of six cycles. Each cycle is a total of 21 days. RCHOP consists of 375 mg/m2 IV rituximab, 750 mg/m2 IV cyclophosphamide, 50 mg/m2 IV doxorubicin, 1.4 mg/m2 IV vincristine and 100 mg/m2 by mouth QD prednisone. The study includes a Phase I component to determine the maximum tolerated dose of everolimus and the second component determines the feasibility of therapy administered to lymphoma patients.
OBJECTIVE: We aimed to investigate the effectiveness of the laparoscopic pectopexy procedure in women who want to preserve their uterus for stage III or IV apical prolapse.
STUDY DESIGN: 132 women who underwent laparoscopic pectopexy due to stage III or IV apical pelvic organ prolapse (POP) were included in this study. Demographic data of the patients, duration of surgery, blood loss, hospitalisation, intraoperative and postoperative complications, recurrence rate were searched from the hospital file archive. Pelvic organ prolapse quantification (POP-Q) system was used at postoperative control visits. The patients' quality of life was evaluated by comparing the results of the pelvic organ quality of life (P-QOL) questionnaire which they filled out at the preoperative and 6th months later.
RESULTS: The patients' mean age was 60(52-66)years. The average duration of the surgery was 110(90-150) minutes. Average blood loss was 150(75-220) ml. No intraoperative or postoperative complications were noted. The average hospitalisation was 2(1-3) days. The average follow-up period was 19 (13-26) months. Apical prolapse recurrence was observed in 3 (2.2 %) patients and laparoscopic sacrohysteropexy was performed. There was a significant improvement in the POP-Q scores of the patients in the postoperative period (p < 0.0001). A significant improvement was detected in the P-QOL total score and all each paramaters after surgery (p < 0.0001).
CONCLUSION: Laparoscopic pectopexy seems to be a reliable and efficient method for patients in advanced stages apical prolapse whom wants to preservation of the uterus.With all the advantages of minimally invasive surgery, it increases the patients' quality of life.
Epidural catheters will be placed at the L3/4 or L4/5 interspace with 4 cm of catheter being left in the epidural space. Epidural analgesia will be initiated and maintained with a solution of ropivacaine 0.1% with fentanyl 2 mcg/ml. After the initial epidural loading dose of 20 mL is administered in incremental fashion, patients will receive 8mL/hr of continuous infusion beginning immediately after the loading dose for the maintenance of analgesia in the CEI arm. All study participants will be provided with PCEA set to 8mL boluses with a10-minute lockout period. The maximum amount of PCEA analgesia will be set to a 1-hour maximum of 45mL.
Divalproex sodium is a stable co-ordination compound comprised of sodium valproate and valproic acid in a 1:1 molar relationship. Chemically it is designated as sodium hydrogen bis (2-propylpentanoate). Divalproex sodium has the following structure: 

Divalproex sodium USP occurs as a white crystalline powder with a characteristic odor.

Divalproex sodium extended-release tablets USP 250 mg and 500 mg are for oral administration. Divalproex sodium extended-release tablets USP contain divalproex sodium USP in a once-a-day extended-release formulation equivalent to 250 mg and 500 mg of valproic acid.

Inactive Ingredients: FD&C Blue #1, FD&C Blue #2, hypromellose, mannitol, polyacrylate dispersion 40 percent, polyethylene glycol, pregelatinised starch (maize), propylene glycol, shellac glaze in ethanol, silicified microcrystalline cellulose, silicon dioxide, titanium dioxide, and triacetin. In addition, 500 mg tablets contain iron oxide black, iron oxide yellow, and polydextrose.

Meets USP dissolution test 7.
Parkinson's disease (PD) is a neurodegenerative condition that results in dyskinesia, with oxidative stress playing a pivotal role in its progression. Antioxidant peptides may thus present therapeutic potential for PD. In this study, a novel cathelicidin peptide (Cath-KP; GCSGRFCNLFNNRRPGRLTLIHRPGGDKRTSTGLIYV) was identified from the skin of the Asiatic painted frog ( Kaloula pulchra). Structural analysis using circular dichroism and homology modeling revealed a unique αββ conformation for Cath-KP. In vitro experiments, including free radical scavenging and ferric-reducing antioxidant analyses, confirmed its antioxidant properties. Using the 1-methyl-4-phenylpyridinium ion (MPP +)-induced dopamine cell line and 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced PD mice, Cath-KP was found to penetrate cells and reach deep brain tissues, resulting in improved MPP +-induced cell viability and reduced oxidative stress-induced damage by promoting antioxidant enzyme expression and alleviating mitochondrial and intracellular reactive oxygen species accumulation through Sirtuin-1 (Sirt1)/Nuclear factor erythroid 2-related factor 2 (Nrf2) pathway activation. Both focal adhesion kinase (FAK) and p38 were also identified as regulatory elements. In the MPTP-induced PD mice, Cath-KP administration increased the number of tyrosine hydroxylase (TH)-positive neurons, restored TH content, and ameliorated dyskinesia. To the best of our knowledge, this study is the first to report on a cathelicidin peptide demonstrating potent antioxidant and neuroprotective properties in a PD model by targeting oxidative stress. These findings expand the known functions of cathelicidins, and hold promise for the development of therapeutic agents for PD.
Methylphenidate hydrochloride chewable tablets should be initiated in small doses, with gradual weekly increments. Daily dosage above 60 mg is not recommended.

If paradoxical aggravation of symptoms or other adverse effects occur, reduce dosage, or, if necessary, discontinue methylphenidate hydrochloride chewable tablet. Methylphenidate hydrochloride chewable tablet should be periodically discontinued to assess the patient's condition. If improvement is not observed after appropriate dosage adjustment over a one-month period, the drug should be discontinued.

Chewable Tablets: Start with 5 mg twice daily (before breakfast and lunch) with gradual increments of 5 to 10 mg weekly.

Drug treatment should not and need not be indefinite and usually may be discontinued after puberty.
The invention relates to an allium macrostemon preparation for preventing intestinal adhesions and a preparation method thereof. The preparation comprises a pharmaceutical active ingredient of allium macrostemon water extract and can be prepared into an allium macrostemon decocted extract, granules and an allium macrostemon capsule preparation. The preparation method comprises the following steps of: decocting allium macrostemon with water to obtain a decocted extract, volatile oil and a water extract; and then preparing allium macrostemon granules and allium macrostemon capsules according to a conventional process of capsules and granules. In the invention, the formation of adhesion is controlled according to the principle that the allium macrostemon can enhance peristalsis and excite the small intestines and the whole digestive tract to have a rhythm effect, and the allium macrostemon has the function of preventing the intestinal adhesion, thus the allium macrostemon preparation capable of preventing intestinal adhesion and adhesive intestinal obstruction is prepared. If the allium macrostemon preparation is used at an early stage, the allium macrostemon preparation has a stronger prevention effect on postoperation intestinal adhesions of patients undergoing abdominal operations, intestinal functions of the patients can be quickly recovered, and the patients can eat food early. The allium macrostemon can be eaten, thus the allium macrostemon preparation can be served as food and a medicine; the allium macrostemon preparation has low price and is convenient to produce and take; and after the allium macrostemon preparation is taken, no adverse reactions appear, thus the allium macrostemon preparation is safe and effective. Proved by animal experiments and clinical experiments, the allium macrostemon preparation causes no adverse reactions.
BACKGROUND: Non-communicable diseases are a global health problem. The metric Disability-Adjusted Life Years was developed to measure its impact on health systems. This metric makes it possible to understand a disease's burden, towards defining healthcare policies. This research analysed the effect of healthcare expenditures in the evolution of disability-adjusted life years for non-communicable diseases in the European Union between 2000 and 2019.
METHODS: Data were collected for all 27 European Union countries from Global Burden of Disease 2019, Global Health Expenditure, and EUROSTAT databases. Econometric panel data models were used to assess the impact of healthcare expenses on the disability-adjusted life years. Only models with a coefficient of determination equal to or higher than 10% were analysed.
RESULTS: There was a decrease in the non-communicable diseases with the highest disability-adjusted life years: cardiovascular diseases (-2,952 years/105 inhabitants) and neoplasms (-618 years/105 inhabitants). Health expenditure significantly decreased disability-adjusted life years for all analysed diseases (p < 0.01) unless for musculoskeletal disorders. Private health expenditure did not show a significant effect on neurological and musculoskeletal disorders (p > 0.05) whereas public health expenditure did not significantly influence skin and subcutaneous diseases (p > 0.05).
CONCLUSION: Health expenditure have proved to be effective in the reduction of several diseases. However, some categories such as musculoskeletal and mental disorders must be a priority for health policies in the future since, despite their low mortality, they can present high morbidity and disability.
PURPOSE: An ester oil of amyl alcohol or an isomer thereof, and fatty acid of natural vegetable oil in a cosmetic composition is provided to ensure superior moisturizing ability, softness, and stability by increasing viscosity of a cosmetic material. CONSTITUTION: A cosmetic composition contains an ester oil as an active ingredient, which is prepared by mixing amyl alcohol or an isomer thereof and fatty acid derived from natural vegetable oil, and esterifying the mixture. The isomer is selected from the group consisting of 3-methyl-1-butanol(isoamyl alcohol), 2-methyl-1-butanol, 2,2-dimethyl-1-propanol, 3-pentanol, 2-pentanol, 3-methyl-2-butanol, and 2-methyl-2-butanol. The natural vegetable oil is olive oil or coconut oil. The fatty acid is a mixture of fatty acid which is extracted by a high temperature and high pressure process. The ester oil is isoamyl oleate selected from structural formulas 15-20.